Merck begins making molybdenum in Korea for next-generation chips

Merck, a German semiconductor materials company, opened a molybdenum precursor plant in South Korea to supply next-gen memory chips. The facility supports major memory makers like Samsung Electronics and SK Hynix. Merck aims to leverage South Korea's semiconductor market and plans to expand applications to DRAM and logic chips. The company has invested €600 million in South Korea and predicts strong demand growth driven by AI.

Merck opened a new molybdenum precursor production facility in South Korea to support advanced semiconductor manufacturing. The facility, part of Merck's strategy to integrate materials and delivery systems, aims to improve supply chain reliability and support customers in developing next-generation semiconductor technologies. Merck has invested significantly in South Korea, positioning it as a key hub for its semiconductor materials business.

Merck will build a molybdenum production facility in Eumseong, South Korea, to support next-gen semiconductor materials. The company aims to integrate local production with supply systems to meet customer needs. Merck forecasts growing demand for molybdenum in semiconductor manufacturing, though adoption rates may vary. The facility will produce specialty precursors for CVD and ALD processes, with a focus on mass production and stable supply.

The European Commission approved pembrolizumab (Keytruda) plus enfortumab vedotin (Padcev) for resectable muscle-invasive bladder cancer (MIBC). The approval, based on KEYNOTE-B15 trial data, shows improved 2-year event-free survival (79.4% vs 66.2%) and overall survival (86.9% vs 81.3%) compared to chemotherapy. The combination is approved for use regardless of cisplatin eligibility. According to Merck, this offers a chemotherapy-free treatment option for MIBC patients in the EU.

The European Commission approved Merck's (MRK) Keytruda combined with Pfizer/Astellas' Padcev for bladder cancer. MRK's dividend yield is 2.4% with a high payout ratio of 1.11, and its stock is 22.9% overvalued per GF Value. MRK's GF Score is 79, showing strong profitability but middling momentum and financial strength. Insiders sold $71.4M in shares, with mixed institutional sentiment.

The European Commission approved a combination of Merck's Keytruda and Pfizer/Astellas' Padcev for treating muscle-invasive bladder cancer. This is the first such approval in Europe for a PD-1 inhibitor. According to the companies, the regimen is intended for resectable cases.